EyePoint Pharmaceuticals

Investor Relations Home

EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.

Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology. ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing authorization in 14 other EU countries.

EyePoint Pharmaceuticals’ other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system.

View all »   RSS

Recent Releases

Apr 19, 2018
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information

Apr 18, 2018
EyePoint Pharmaceuticals' YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

View all »

Events & Presentations

May 8, 2018 at 4:30 PM ET
Q3 2018 EyePoint Pharmaceuticals Earnings Conference Call

IR Contacts

Barbara Ryan
(203) 274-2825

Michael Polyviou
(732) 933-2754

Transfer Agent:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA
Phone: 781-575-2879
Fax: 781-575-3605

EyePoint Pharmaceuticals